Buckeye Concussion Knowledge Survey (BUCKS)
The purpose of this study is to examine health outcomes in former Ohio State University athletes who played a varsity sport during their time at OSU. The objective is to determine whether athletes who sustained a concussion have different health outcomes than those who did not sustain a concussion. Any former OSU varsity athlete can participate in a 20-minute online survey.
- Anyone who has played a varsity sport as an undergraduate student at OSU, and they have now graduated (i.e., OSU athlete alumni). There are no other restrictions in terms of age, sex/gender, type of sport, etc.
Blood Pressure Health for Black/African American Women Caregivers
The purpose of this study is to determine the feasibility of a group delivered intervention for stress and blood pressure in African American women caregivers.
- Diagnosis of HTN treated with an antihypertensive medication or risk of HTN that includes obesity and high cholesterol
- Age 40 and older
- A caregiver rating of the PLWD of 2 or greater on the Alzheimer’s Dementia-8 scale
- Caregiver provides unpaid care to a PLWD at least 10 hours per week or assists with at least one instrumental activity of daily living
- Self-identifies as Black/African American
- English speaking
- Access to a telecommunications device such as the internet via desktop, laptop/tablet, smartphone, or telephone
Stress Reactivity Study
The purpose of this study is to see if BELSOMRA, an FDA approved medication that is prescribed to treat insomnia, changes the body’s response to stress.
Eligibility Criteria:
- 18-65 years old
- Generally medically and physically healthy
- Regular alcohol use
Exclusion Criteria:
- Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
- Currently pregnant or trying to become pregnant (female)
- Presence of ferrous-containing metal in the body
- Inability to tolerate enclosed spaces
Exclusion Criteria varies, please contact Study Coordinator for more information.
A Study About the Development of Learning in African-American/Black Children
The purpose of this study is to investigate the early development of attention, learning, and memory during childhood. Participation in this study includes 4, 90-minute-long visits to the lab per year. During these visits, your child will play 2-3 fun, computerized games. These games are designed to assess various aspects of their cognitive ability.
The duration of the study will last 4 years.
Eligibility Criteria:
- African-American/Black children who are 4 years old
Sleep and Blood Sugar in People with Alzheimer's Disease
The purpose of this study is to learn about sleep and blood sugar (glucose) levels in people living with Alzheimer’s disease (AD). Another purpose of the study is to see how people with AD and their caregivers/family members feel about wearing small devices to measure sleep and blood sugar.
The duration of this study is 10 days.
- 60 years or older, with Alzheimer’s disease,
- Has a caregiver 18 years or older,
- Willing to wear a watch-like device,
- Willing to wear a small sensor on the skin
An Intervention Study to Evaluate a Medication (MIJ821) Used to Treat Major Depressive Disorder
The purpose of the study is to determine if the investigational study drug will rapidly reduce depression associated with thoughts of harming oneself when given in addition to standard antidepressant medication.
Your participation in this study will last for a minimum of 14 weeks and maximum of 58 weeks.
• Aged 18-65 years old
• Diagnosed with major depressive disorder (MDD) with a current major depressive episode
• Having current suicidal ideation with intent
• Already in the hospital or agree to be hospitalized voluntarily for the required period of time
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is being done to see if the study drug, called BI 1358894, compared to a drug called quetiapine, may help people with Major Depressive Disorder (MDD) who do not progress when taking an antidepressant medication alone. This study will help to gain information for providing better or new possible treatments for people in the future.
This study will take place over a period of 13 weeks and have about 8 visits to the study center and 2 that will be done by phone.
• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking an antidepressant
A Study to Evaluate the Safety of REL-1017, A Study Drug Used to Treat Major Depressive Disorder (MDD)
This is a 1-year open-label study to access the safety of REL-1017, a study medication, once daily as a workable treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.
This study will last 13 months and you will come to the study site at least 15 times over this period. This will include 1 final visit about 1 month after you stop taking the study drug.
• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking or having taken between 1 and 3 antidepressants for the current episode of depression
Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults with Major Depressive Disorder (MDD) (SAVITRI)
The purpose of this study is to evaluate the effectiveness and safety of NBI-1065845 compared with placebo. In addition to the study drug, participants will continue their normal antidepressant medications. The main goal of this study is to examine the improving symptoms of depression.
The duration of the study will last 14 weeks, including up to 4 weeks of screening, 8 weeks of study drug dosing, and a follow-up period of 2 weeks.
• Aged 18-65 years old
• Have a diagnosis of Major Depressive Disorder (MDD)
• Currently depressed
• Poor response to antidepressant treatment
A Study to Evaluate the Effectiveness and Safety of NBI-1065846 (TERPIS)
To evaluate the efficacy and safety of study drug NBI-1065846, used as adjunctive treatment to oral antidepressant medication(s), compared with a placebo when treating symptoms of anhedonia.
• Aged 18-65 years old • Diagnosis of MDD • Currently on stable dose of at least one antidepressant • Experiencing anhedonia (low interest, decreased enjoyment)